LIVIVO - Search results -

Search results

Result 1 - 10 of total 50

Search options

Article ; Online: Pertinence des inhibiteurs des points de contrôle immunitaire chez les patients atteints de maladie auto-immune ou inflammatoire.

Danlos, François-Xavier / Lambotte, Olivier

2018 Volume 34, Issue 6-7, Page(s) 516–518

Title translation	Is it possible to use immune checkpoint inhibitors in patients with autoimmune or inflammatory disease?
MeSH term(s)	Antibodies, Monoclonal/adverse effects ; Antibodies, Monoclonal/therapeutic use ; Autoimmune Diseases/drug therapy ; Humans ; Immunologic Factors/adverse effects ; Immunologic Factors/therapeutic use ; Inflammation/drug therapy
Chemical Substances	Antibodies, Monoclonal ; Immunologic Factors
Language	French
Publishing date	2018-07-31
Publishing country	France
Document type	Journal Article
ZDB-ID	632733-3
ISSN	1958-5381 ; 0767-0974
ISSN (online)	1958-5381
ISSN	0767-0974
DOI	10.1051/medsci/20183406007
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.B 2872: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Cancer immunotherapy efficacy is driven by tumour biology, not by its histology. Impact on drug development and approvals.

Bonvalet, Mélodie / Danlos, François-Xavier / Champiat, Stéphane / Rouanne, Mathieu / Marabelle, Aurélien

European journal of cancer (Oxford, England : 1990)

2022 Volume 162, Page(s) 130–132

MeSH term(s)	Biology ; Drug Approval ; Drug Development ; Humans ; Immunotherapy ; Neoplasms/drug therapy ; Neoplasms/pathology
Language	English
Publishing date	2022-01-01
Publishing country	England
Document type	Editorial
ZDB-ID	82061-1
ISSN	1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
ISSN (online)	1879-0852
ISSN	0277-5379 ; 0959-8049 ; 0964-1947
DOI	10.1016/j.ejca.2021.12.004
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 456: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 583: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Chemokine biology on immune checkpoint-targeted therapies.

Letourneur, Diane / Danlos, François-Xavier / Marabelle, Aurélien

European journal of cancer (Oxford, England : 1990)

2020 Volume 137, Page(s) 260–271

Abstract: The use of antagonistic immune checkpoint-targeted monoclonal antibodies has profoundly modified the standard of care and significantly increased the survival for many cancers. However, many patients still do not respond to those treatments. Biomarkers ... ...

Abstract	The use of antagonistic immune checkpoint-targeted monoclonal antibodies has profoundly modified the standard of care and significantly increased the survival for many cancers. However, many patients still do not respond to those treatments. Biomarkers predictive for efficacy or failure of such immunotherapies would allow developing treatment stratification strategies which could further increase the survival rates of patients with cancer. Chemokines are a subset of the immune cell messenger molecules known as cytokines. Chemokines are key chemoattractant molecules which are essential for the homing of immune cells, notably within tumours. Therefore, they are good candidates for providing predictive biomarkers of the clinical response to checkpoint blockade immunotherapies. In this review, we summarise the recent advances in our understanding of the role of chemokines and how chemokine concentrations may set the tone for the efficacy of immune checkpoint-targeted immunotherapies.
MeSH term(s)	Chemokines/metabolism ; Humans ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/therapeutic use
Chemical Substances	Chemokines ; Immune Checkpoint Inhibitors
Language	English
Publishing date	2020-08-18
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	82061-1
ISSN	1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
ISSN (online)	1879-0852
ISSN	0277-5379 ; 0959-8049 ; 0964-1947
DOI	10.1016/j.ejca.2020.06.009
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 456: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 583: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Impact of immunosuppressive agents on the management of immune-related adverse events of immune checkpoint blockers.

Cariou, Pierre-Louis / Pobel, Cédric / Michot, Jean-Marie / Danlos, François-Xavier / Besse, Benjamin / Carbonnel, Franck / Mariette, Xavier / Marabelle, Aurélien / Messayke, Sabine / Robert, Caroline / Routier, Emilie / Noël, Nicolas / Lambotte, Olivier

European journal of cancer (Oxford, England : 1990)

2024 Volume 204, Page(s) 114065

Abstract: Background: Immune checkpoint blockers (ICBs) can induce immune-related adverse events (irAEs) whose management is based on expert opinion and may require the prescription of steroids and/or immunosuppressants (ISs). Recent data suggest that these ... ...

Abstract	Background: Immune checkpoint blockers (ICBs) can induce immune-related adverse events (irAEs) whose management is based on expert opinion and may require the prescription of steroids and/or immunosuppressants (ISs). Recent data suggest that these treatments can reduce the effectiveness of ICBs. Objective: To investigate the relationship between the use of steroids and/or ISs and overall survival (OS) and progression-free survival (PFS) among ICB-treated patients with an irAE. Methods: We prospectively collected data from the medical records of patients with solid tumors or lymphoma in the French REISAMIC cohort and who had been treated with ICBs between June 2014 and June 2020. Results: 184 ICB-treated patients experienced at least one Common Terminology Criteria for Adverse Events grade ≥ 2 irAE. 107 (58.2%) were treated with steroids alone, 20 (10.9%) with steroids plus IS, 57 (31.0%) not received steroids or IS. The median OS was significantly shorter for patients treated with steroids alone (25.2 months [95% confidence interval (CI): 22.3-32.4] than for patients treated without steroids or IS (63 months [95%CI: 40.4-NA]) and those receiving an IS with steroids (53.4 months [95%CI: 47.3-NA]) (p < 0.001). The median PFS was significantly shorter for patients treated with steroids alone (17.0 months [95%CI: 11.7-22.9]) than for patients treated without steroids or IS (33.9 months [95%CI: 18.0-NA]) and those receiving an IS with steroids (41.1 months [95%CI: 26.2-NA]) (p = 0.006). There were no significant intergroup differences in the hospital admission and infection rates. Conclusion: In a prospective cohort of ICB-treated patients, the use of IS was not associated with worse OS or PFS, contrasting with the use of steroids for the management of irAEs.
Language	English
Publishing date	2024-04-14
Publishing country	England
Document type	Journal Article
ZDB-ID	82061-1
ISSN	1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
ISSN (online)	1879-0852
ISSN	0277-5379 ; 0959-8049 ; 0964-1947
DOI	10.1016/j.ejca.2024.114065
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 456: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 583: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Drug-induced autoimmune hemolytic anemias related to immune checkpoint inhibitors, therapeutic management, and outcome.

Plaçais, Marion / Laparra, Ariane / Maria, Alexandre Thibault Jacques / Kramkimel, Nora / Perret, Audrey / Manson, Guillaume / Comont, Thibault / Coutte, Laetitia / Nardin, Charlee / Ouali, Kaissa / Danlos, Francois-Xavier / Noël, Nicolas / Messayke, Sabine / Michel, Marc / Lambotte, Olivier / Michot, Jean-Marie

American journal of hematology

2024

Language	English
Publishing date	2024-04-20
Publishing country	United States
Document type	Letter
ZDB-ID	196767-8
ISSN	1096-8652 ; 0361-8609
ISSN (online)	1096-8652
ISSN	0361-8609
DOI	10.1002/ajh.27339
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 1251: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (1.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: Phase 1 first-in-human dose-escalation study of ANV419 in patients with relapsed/refractory advanced solid tumors.

Mathiot, Laurent / Combarel, David / Cagnat, Justin / Delahousse, Julia / Ouali, Kaissa / Marabelle, Aurelien / Loriot, Yohann / Ponce, Santiago / Champiat, Stephane / Broutin, Sophie / Danlos, Francois-Xavier

Journal for immunotherapy of cancer

2024 Volume 12, Issue 5

Abstract: Patients with advanced cancer, previously treated with immune checkpoint blockade therapy, may retain residual treatment when undergoing the initial infusion of experimental monotherapy in phase 1 clinical trials. ANV419, an antibody-cytokine fusion ... ...

Abstract	Patients with advanced cancer, previously treated with immune checkpoint blockade therapy, may retain residual treatment when undergoing the initial infusion of experimental monotherapy in phase 1 clinical trials. ANV419, an antibody-cytokine fusion protein, combines interleukin-2 (IL-2) with an anti-IL-2 monoclonal antibody, aiming to stimulate the expansion of CD8 T and natural killer lymphocytes while restricting regulatory T lymphocytes. In the recent publication of the phase 1 dose escalation study of ANV419, a notable gap exists in detailed information regarding patients' prior antitumoral treatments, specifically programmed death-1/programmed death-ligand 1 (PD-1/PD-L1) targeted monoclonal antibodies. Some patients likely retained residual anti-PD-1/PD-L1 monoclonal antibodies, potentially influencing the outcomes of ANV419. In a separate clinical cohort, we retrospectively measured the residual concentration of nivolumab and pembrolizumab, revealing persistent serum concentrations of anti-PD-1/PD-L1 antibodies even months after treatment cessation. This underscores the importance of comprehensively documenting prior immunotherapy details in clinical trials. Such information is crucial for understanding potential interactions that may impact both immunological and clinical effects.
MeSH term(s)	Humans ; Neoplasms/drug therapy ; Neoplasms/immunology ; Male ; Female ; Middle Aged ; Aged ; Interleukin-2/therapeutic use ; Interleukin-2/administration & dosage ; Antibodies, Monoclonal, Humanized/therapeutic use ; Antibodies, Monoclonal, Humanized/administration & dosage ; Immune Checkpoint Inhibitors/therapeutic use ; Immune Checkpoint Inhibitors/pharmacology ; Immune Checkpoint Inhibitors/administration & dosage ; Adult ; Recombinant Fusion Proteins/therapeutic use ; Recombinant Fusion Proteins/administration & dosage
Chemical Substances	Interleukin-2 ; Antibodies, Monoclonal, Humanized ; Immune Checkpoint Inhibitors ; Recombinant Fusion Proteins
Language	English
Publishing date	2024-05-03
Publishing country	England
Document type	Journal Article ; Clinical Trial, Phase I ; Research Support, Non-U.S. Gov't
ZDB-ID	2719863-7
ISSN	2051-1426 ; 2051-1426
ISSN (online)	2051-1426
ISSN	2051-1426
DOI	10.1136/jitc-2024-008847
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Intratumoral Immunotherapy: Is It Ready for Prime Time?

Ghosn, Mario / Tselikas, Lambros / Champiat, Stéphane / Deschamps, Frederic / Bonnet, Baptiste / Carre, Émilie / Testan, Marine / Danlos, François-Xavier / Farhane, Siham / Susini, Sandrine / Suzzoni, Steve / Ammari, Samy / Marabelle, Aurélien / De Baere, Thierry

Current oncology reports

2023 Volume 25, Issue 8, Page(s) 857–867

Abstract: Purpose of review: This review presents the rationale for intratumoral immunotherapy, technical considerations and safety. Clinical results from the latest trials are provided and discussed.: Recent findings: Intratumoral immunotherapy is feasible ... ...

Abstract	Purpose of review: This review presents the rationale for intratumoral immunotherapy, technical considerations and safety. Clinical results from the latest trials are provided and discussed. Recent findings: Intratumoral immunotherapy is feasible and safe in a wide range of cancer histologies and locations, including lung and liver. Studies mainly focused on multi-metastatic patients, with some positive trials such as T-VEC in melanoma, but evidence of clinical benefit is still lacking. Recent results showed improved outcomes in patients with a low tumor burden. Intratumoral immunotherapy can lower systemic toxicities and boost local and systemic immune responses. Several studies have proven the feasibility, repeatability, and safety of this approach, with some promising results in clinical trials. The clinical benefit might be improved in patients with a low tumor burden. Future clinical trials should focus on adequate timing of treatment delivery during the course of the disease, particularly in the neoadjuvant setting.
MeSH term(s)	Humans ; Melanoma/pathology ; Neoadjuvant Therapy ; Immunotherapy/methods ; Immunity
Language	English
Publishing date	2023-05-02
Publishing country	United States
Document type	Journal Article ; Review ; Research Support, Non-U.S. Gov't
ZDB-ID	2057359-5
ISSN	1534-6269 ; 1523-3790
ISSN (online)	1534-6269
ISSN	1523-3790
DOI	10.1007/s11912-023-01422-4
Database	MEDical Literature Analysis and Retrieval System OnLINE

Full text online

Accessible to users with ZB MED library card

In stock of ZB MED Cologne/Königswinter

Zs.A 5521: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
Jg. 1995 - 2021: Lesesall (2.OG)
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾

Article ; Online: Repurposing of Anticancer Drugs Expands Possibilities for Antiviral and Anti-Inflammatory Discovery in COVID-19.

Aldea, Mihaela / Michot, Jean-Marie / Danlos, Francois-Xavier / Ribas, Antoni / Soria, Jean-Charles

Cancer discovery

2021 Volume 11, Issue 6, Page(s) 1336–1344

Abstract: In 2020, the COVID-19 pandemic led to an unprecedented destabilization of the world's health and economic systems. The rapid spread and life-threatening consequences of COVID-19 have imposed testing of repurposed drugs, by investigating interventions ... ...

Abstract	In 2020, the COVID-19 pandemic led to an unprecedented destabilization of the world's health and economic systems. The rapid spread and life-threatening consequences of COVID-19 have imposed testing of repurposed drugs, by investigating interventions already used in other indications, including anticancer drugs. The contours of anticancer drug repurposing have been shaped by similarities between the pathogenesis of COVID-19 and malignancies, including abnormal inflammatory and immunologic responses. In this review, we discuss the salient positive and negative points of repurposing anticancer drugs to advance treatments for COVID-19. SIGNIFICANCE: Targeting anti-inflammatory pathways with JAK/STAT inhibitors or anticytokine therapies aiming to curb COVID-19-related cytokine storm, using antiangiogenic drugs to reduce vascular abnormalities or immune-checkpoint inhibitors to improve antiviral defenses, could be of value in COVID-19. However, conflicting data on drug efficacy point to the need for better patient selection and biomarker studies.
MeSH term(s)	Anti-Inflammatory Agents/pharmacology ; Anti-Inflammatory Agents/therapeutic use ; Antineoplastic Agents/pharmacology ; Antineoplastic Agents/therapeutic use ; Antiviral Agents/pharmacology ; Antiviral Agents/therapeutic use ; COVID-19/drug therapy ; COVID-19/immunology ; Drug Repositioning ; Evidence-Based Medicine ; Humans ; Patient Selection ; SARS-CoV-2/drug effects ; SARS-CoV-2/immunology
Chemical Substances	Anti-Inflammatory Agents ; Antineoplastic Agents ; Antiviral Agents
Language	English
Publishing date	2021-04-12
Publishing country	United States
Document type	Journal Article ; Review
ZDB-ID	2625242-9
ISSN	2159-8290 ; 2159-8274
ISSN (online)	2159-8290
ISSN	2159-8274
DOI	10.1158/2159-8290.CD-21-0144
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 6916: Show issues

Location:
Je nach Verfügbarkeit (siehe Angabe bei Bestand)
bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
ab Jg. 2022: Lesesaal (EG)

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

Article ; Online: B cells and the coordination of immune checkpoint inhibitor response in patients with solid tumors.

Flippot, Ronan / Teixeira, Marcus / Rey-Cardenas, Macarena / Carril-Ajuria, Lucia / Rainho, Larissa / Naoun, Natacha / Jouniaux, Jean-Mehdi / Boselli, Lisa / Naigeon, Marie / Danlos, Francois-Xavier / Escudier, Bernard / Scoazec, Jean-Yves / Cassard, Lydie / Albiges, Laurence / Chaput, Nathalie

Journal for immunotherapy of cancer

2024 Volume 12, Issue 4

Abstract: Immunotherapy profoundly changed the landscape of cancer therapy by providing long-lasting responses in subsets of patients and is now the standard of care in several solid tumor types. However, immunotherapy activity beyond conventional immune ... ...

Abstract	Immunotherapy profoundly changed the landscape of cancer therapy by providing long-lasting responses in subsets of patients and is now the standard of care in several solid tumor types. However, immunotherapy activity beyond conventional immune checkpoint inhibition is plateauing, and biomarkers are overall lacking to guide treatment selection. Most studies have focused on T cell engagement and response, but there is a growing evidence that B cells may be key players in the establishment of an organized immune response, notably through tertiary lymphoid structures. Mechanisms of B cell response include antibody-dependent cellular cytotoxicity and phagocytosis, promotion of CD4+ and CD8+ T cell activation, maintenance of antitumor immune memory. In several solid tumor types, higher levels of B cells, specific B cell subpopulations, or the presence of tertiary lymphoid structures have been associated with improved outcomes on immune checkpoint inhibitors. The fate of B cell subpopulations may be widely influenced by the cytokine milieu, with versatile roles for B-specific cytokines B cell activating factor and B cell attracting chemokine-1/CXCL13, and a master regulatory role for IL-10. Roles of B cell-specific immune checkpoints such as TIM-1 are emerging and could represent potential therapeutic targets. Overall, the expanding field of B cells in solid tumors of holds promise for the improvement of current immunotherapy strategies and patient selection.
MeSH term(s)	Humans ; Immune Checkpoint Inhibitors ; Tertiary Lymphoid Structures ; Neoplasms ; Cytokines/metabolism ; Lymphocyte Activation
Chemical Substances	Immune Checkpoint Inhibitors ; Cytokines
Language	English
Publishing date	2024-04-16
Publishing country	England
Document type	Journal Article ; Review
ZDB-ID	2719863-7
ISSN	2051-1426 ; 2051-1426
ISSN (online)	2051-1426
ISSN	2051-1426
DOI	10.1136/jitc-2023-008636
Database	MEDical Literature Analysis and Retrieval System OnLINE

Order via subito

Article ; Online: Applications of single-cell and bulk RNA sequencing in onco-immunology.

Kuksin, Maria / Morel, Daphné / Aglave, Marine / Danlos, François-Xavier / Marabelle, Aurélien / Zinovyev, Andrei / Gautheret, Daniel / Verlingue, Loïc

European journal of cancer (Oxford, England : 1990)

2021 Volume 149, Page(s) 193–210

Abstract: The rising interest for precise characterization of the tumour immune contexture has recently brought forward the high potential of RNA sequencing (RNA-seq) in identifying molecular mechanisms engaged in the response to immunotherapy. In this review, we ... ...

Abstract	The rising interest for precise characterization of the tumour immune contexture has recently brought forward the high potential of RNA sequencing (RNA-seq) in identifying molecular mechanisms engaged in the response to immunotherapy. In this review, we provide an overview of the major principles of single-cell and conventional (bulk) RNA-seq applied to onco-immunology. We describe standard preprocessing and statistical analyses of data obtained from such techniques and highlight some computational challenges relative to the sequencing of individual cells. We notably provide examples of gene expression analyses such as differential expression analysis, dimensionality reduction, clustering and enrichment analysis. Additionally, we used public data sets to exemplify how deconvolution algorithms can identify and quantify multiple immune subpopulations from either bulk or single-cell RNA-seq. We give examples of machine and deep learning models used to predict patient outcomes and treatment effect from high-dimensional data. Finally, we balance the strengths and weaknesses of single-cell and bulk RNA-seq regarding their applications in the clinic.
MeSH term(s)	Artificial Intelligence ; Biomarkers, Tumor/genetics ; Clinical Decision-Making ; Gene Expression Profiling ; Humans ; Neoplasms/drug therapy ; Neoplasms/genetics ; Neoplasms/immunology ; Neoplasms/pathology ; Precision Medicine ; Predictive Value of Tests ; Prognosis ; RNA, Neoplasm/genetics ; RNA-Seq ; Single-Cell Analysis ; Transcriptome ; Tumor Microenvironment/immunology
Chemical Substances	Biomarkers, Tumor ; RNA, Neoplasm
Language	English
Publishing date	2021-04-15
Publishing country	England
Document type	Journal Article ; Research Support, Non-U.S. Gov't ; Review
ZDB-ID	82061-1
ISSN	1879-0852 ; 0277-5379 ; 0959-8049 ; 0964-1947
ISSN (online)	1879-0852
ISSN	0277-5379 ; 0959-8049 ; 0964-1947
DOI	10.1016/j.ejca.2021.03.005
Database	MEDical Literature Analysis and Retrieval System OnLINE

In stock of ZB MED Cologne/Königswinter

Zs.A 456: Show issues			Location: Je nach Verfügbarkeit (siehe Angabe bei Bestand) bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular Jg. 1995 - 2021: Lesesall (1.OG) ab Jg. 2022: Lesesaal (EG)
Zs.MO 583: Show issues

Order via subito

Details ▾
- See ZB MED holdings
- Order with fees

To top

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

Full text online

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito

More links

Kategorien

Order via subito

More links

Kategorien

In stock of ZB MED Cologne/Königswinter

Order via subito